In English | En español
Questions About Cancer? 1-800-4-CANCER

Renal Cell Cancer Treatment (PDQ®)

  • Last Modified: 02/21/2014

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document

Changes to This Summary (02/21/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Renal Cell Cancer

Updated statistics with estimated new cases and deaths for 2014 (cited American Cancer Society as reference 1).

Stage IV and Recurrent Renal Cell Cancer

Added text to state that pazopanib was also compared with sunitinib in a randomized controlled trial that enrolled 1,110 patients who had metastatic renal cell carcinoma with a renal cell component in a 1:1 ratio (cited Motzer et al. as reference 33). Also added that the primary endpoint was progression-free survival (PFS), and the study was powered to assess the noninferiority of pazopanib. The median PFS time was 8.4 months for those in the pazopanib arm and 9.5 months for those in the sunitinib arm, and there was no difference in overall survival; quality of life was also compared in the study.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.